专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明申请

US20130251726A1 NOVEL HIV -1 BROADLY NEUTRALIZING ANTIBODIES 有权
标题翻译：新型艾滋病毒-1广泛抗中性抗体
公开(公告)号：US20130251726A1
公开(公告)日：2013-09-26
申请号：US13792098
申请日：2013-03-10
申请人： John Mascola , Dennis R. Burton , Wayne Koff , Peter Kwong , Gary Nabel , Sanjay K. Phogat , Pascal Raymond Georges Poignard , Melissa Danielle De Jean St. Marcel Simek-Lemos , Xueling Wu , Tongqing Zhou , Zhi-Yong Yang
发明人： John Mascola , Dennis R. Burton , Wayne Koff , Peter Kwong , Gary Nabel , Sanjay K. Phogat , Pascal Raymond Georges Poignard , Melissa Danielle De Jean St. Marcel Simek-Lemos , Xueling Wu , Tongqing Zhou , Zhi-Yong Yang
IPC分类号： C07K16/10 , A61K45/06 , A61K39/42
CPC分类号： C07K16/1063 , A61K39/42 , A61K45/06 , A61K2039/505 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/76 , C07K2317/92 , G01N33/56988
摘要： The present application relates novel HIV-1 broadly neutralizing antibodies. The antibodies of the present invention are further characterized by their ability to bind epitopes from the Env proteins. The invention also provides light and heavy chain variable region sequences. Compositions for prophylaxis, diagnosis and treatment of HIV infection are provided.
摘要翻译：本申请涉及新型HIV-1广泛中和抗体。本发明的抗体的特征还在于它们能够结合来自Env蛋白的表位。本发明还提供轻链和重链可变区序列。提供了预防，诊断和治疗艾滋病毒感染的组合。

32. 发明申请

US20120282264A1 NEUTRALIZING ANTIBODIES TO HIV-1 AND THEIR USE 有权
标题翻译：将抗体中和到HIV-1及其使用
公开(公告)号：US20120282264A1
公开(公告)日：2012-11-08
申请号：US13498125
申请日：2010-09-24
申请人： John R. Mascola , Richard Wyatt , Xueling Wu , Yuxing Li , Carl-Magnus Hogerkorp , Mario Roederer , Zhi-yong Yang , Gary Nabel , Peter Kwong , Tongqing Zhou , Mark Connors , Gilad Ofek , Lawrence Shapiro , Jiang Zhu , William R. Schief
发明人： John R. Mascola , Richard Wyatt , Xueling Wu , Yuxing Li , Carl-Magnus Hogerkorp , Mario Roederer , Zhi-yong Yang , Gary Nabel , Peter Kwong , Tongqing Zhou , Mark Connors , Gilad Ofek , Lawrence Shapiro , Jiang Zhu , William R. Schief
IPC分类号： C07K16/10 , A61K39/42 , C12N15/13 , C12N1/21 , C12N15/74 , G01N33/569 , A61P31/18 , G01N33/577 , C12N9/96 , C12N15/63
CPC分类号： C07K16/1063 , A61K39/42 , A61K45/06 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C12N2740/10011 , C12N2740/16011 , C12N2740/16111
摘要： Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and the use of these antibodies are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes.
摘要翻译：公开了特异性结合HIV-1 gp120的CD4结合位点的单克隆中和抗体。还公开了特异性结合HIV-1 gp41的单克隆中和抗体。还公开了这些抗体的鉴定，以及这些抗体的用途。还提供了用于增强使用表位支架探针的任何抗体的结合和中和活性的方法。

33. 发明申请

US20070287682A1 Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor 审中-公开
标题翻译：通过细胞的位点特异性滴注或细胞的位点特异性转化及其试剂盒来治疗疾病
公开(公告)号：US20070287682A1
公开(公告)日：2007-12-13
申请号：US11788728
申请日：2007-04-20
申请人： Elizabeth Nabel , Gary Nabel
发明人： Elizabeth Nabel , Gary Nabel
IPC分类号： A61K31/70 , C07H21/00 , C08B37/02
CPC分类号： A61K39/00 , A61B17/22 , A61B2017/22038 , A61B2017/22054 , A61B2017/22082 , A61B2017/22084 , A61K9/0024 , A61K31/70 , A61K47/6957 , A61K48/00 , A61L29/16 , A61L2300/252 , A61L2300/258 , A61L2300/626 , A61L2300/64
摘要： A method for the direct treatment towards the specific sites of a disease is disclosed. This method is based on the delivery of proteins by catheterization to discrete blood vessel segments using genetically modified or normal cells or other vector systems. Endothelial cells expressing recombinant therapeutic agent or diagnostic proteins are situated on the walls of the blood vessel or in the tissue perfused by the vessel in a patient. This technique, provides for the transfer of cells or vectors and expression of recombinant genes in vivo and allows the introduction of proteins of therapeutic or diagnostic value for the treatment of diseases.
摘要翻译：公开了一种直接治疗疾病特定部位的方法。该方法基于通过导管插入到使用遗传修饰或正常细胞或其他载体系统的离散血管段的蛋白质递送。表达重组治疗剂或诊断性蛋白质的内皮细胞位于血管壁或患者血管灌注的组织中。该技术提供细胞或载体的转移和体内重组基因的表达，并允许引入用于治疗疾病的治疗或诊断价值的蛋白质。

34. 发明申请

US20060239990A1 Protein Arginine N-Methyltransferase 2 (PRMT-2) 审中-公开
标题翻译：蛋白精氨酸N-甲基转移酶2（PRMT-2）
公开(公告)号：US20060239990A1
公开(公告)日：2006-10-26
申请号：US11263657
申请日：2005-10-31
申请人： Elizabeth Nabel , Gary Nabel , Takanobu Yoshimoto , Hiroaki Iwasaki
发明人： Elizabeth Nabel , Gary Nabel , Takanobu Yoshimoto , Hiroaki Iwasaki
IPC分类号： A61K48/00 , A61K38/48
CPC分类号： A01K67/0276 , A01K2217/075 , A01K2227/105 , A01K2267/0362 , A61K31/7105 , A61K38/45 , A61K48/00 , C12N9/1007 , C12N15/8509 , C12N2310/11 , C12N2310/122 , C12N2310/14 , C12Q1/48 , G01N33/573 , G01N33/57496 , G01N2333/91011 , G01N2500/00 , G01N2500/10
摘要： The invention provides insight into the function of Protein Arginine N-Methyltransferase-2 (PRMT-2) and provides methods for modulating PRMT-2 activity or expression in cells. The methods of the invention can be used to inhibit the function of NFκB, E2F1 and STAT3 and have utility for treating a variety of conditions including, for example, inflammation, HIV infection, cancer and obesity.
摘要翻译：本发明提供了蛋白精氨酸N-甲基转移酶-2（PRMT-2）的功能的了解，并提供了调节细胞中PRMT-2活性或表达的方法。本发明的方法可用于抑制NFκB，E2F1和STAT3的功能，并且可用于治疗各种病症，包括炎症，HIV感染，癌症和肥胖症。

35. 发明申请

US20060140919A1 Methods for selectively stimulating proliferation of T cells 有权
公开(公告)号：US20060140919A1
公开(公告)日：2006-06-29
申请号：US11366331
申请日：2006-03-02
申请人： Carl June , Craig Thompson , Gary Nabel , Gary Gray , Paul Rennert
发明人： Carl June , Craig Thompson , Gary Nabel , Gary Gray , Paul Rennert
IPC分类号： A61K39/395 , A61K35/14
CPC分类号： C07K14/705 , A61K2039/5158 , C07K16/2806 , C07K16/2809 , C07K16/2818 , C07K16/2896 , C07K2317/34 , C12N5/0636 , C12N2501/51 , C12N2501/515 , C12N2501/599
摘要： Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.

36. 发明申请

US20060099177A1 Methods for treating HIV infected subjects 失效
公开(公告)号：US20060099177A1
公开(公告)日：2006-05-11
申请号：US11326148
申请日：2006-01-05
申请人： Carl June , Craig Thompson , Gary Nabel , Gary Gray , Paul Rennert
发明人： Carl June , Craig Thompson , Gary Nabel , Gary Gray , Paul Rennert
IPC分类号： A61K35/14 , C12N5/08
CPC分类号： C07K16/2809 , A61K35/17 , A61K2039/507 , C07K16/2806 , C07K16/2818 , C07K2317/34 , C07K2317/55 , C07K2317/74 , C07K2319/30 , C12N2740/16011
摘要： Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.

37. 发明申请

US20050203050A1 hKIS compositions and methods of use 失效
标题翻译： hKIS组合物和使用方法
公开(公告)号：US20050203050A1
公开(公告)日：2005-09-15
申请号：US11128063
申请日：2005-05-12
申请人： Gary Nabel , Elizabeth Nabel , Manfred Boehm
发明人： Gary Nabel , Elizabeth Nabel , Manfred Boehm
IPC分类号： A61K38/00 , A61K48/00 , C07K14/47 , C12N9/12 , C12Q1/68 , C07H21/04
CPC分类号： C12N9/1205 , A61K38/00 , A61K48/00 , C07K14/4738 , C12N2799/022
摘要： Disclosed herein are novel composition and methods for altering the proliferation of a cell. Included are wild-type and mutant hKIS polypeptides along with cyclin kinase inhibitors containing mutations that prevent their inhibition with serine/threonine kinases.
摘要翻译：本文公开了用于改变细胞增殖的新型组合物和方法。包括野生型和突变型hKIS多肽以及含有突变的细胞周期蛋白激酶抑制剂，其具有预防丝氨酸/苏氨酸激酶的抑制作用。

38. 发明授权

US4722998A Method of producing lymphocyte growth factors 失效
标题翻译：产生淋巴细胞生长因子的方法
公开(公告)号：US4722998A
公开(公告)日：1988-02-02
申请号：US872105
申请日：1986-06-05
申请人： Harvey I. Cantor , Gary Nabel
发明人： Harvey I. Cantor , Gary Nabel
IPC分类号： A61K38/00 , A61K47/48 , C07K14/52 , C07G7/02 , A61K35/14 , A61K37/04
CPC分类号： C07K14/52 , A61K47/48423 , A61K38/00 , Y10S530/829 , Y10S530/83
摘要： The present invention is directed to a method of producing growth factors for mammalian cells. More particularly, the method of the present invention comprises isolating mammalian inducer T-lymphocytes, and stimulating growth factor production by contacting these inducer lymphocytes with an antigen or a mitogen. The resulting growth factors are then separated from the material produced by the stimulated lymphocytes.
摘要翻译：本发明涉及一种生产哺乳动物细胞生长因子的方法。更具体地，本发明的方法包括分离哺乳动物诱导物T淋巴细胞，并通过使这些诱导物淋巴细胞与抗原或丝裂原接触来刺激生长因子产生。然后将所得到的生长因子与被刺激的淋巴细胞产生的物质分离。

39. 发明授权

US4559310A Assay methods and systems utilizing mast cell clones 失效
标题翻译：使用肥大细胞克隆的测定方法和系统
公开(公告)号：US4559310A
公开(公告)日：1985-12-17
申请号：US496543
申请日：1983-05-20
申请人： Harvey I. Cantor , Gary Nabel
发明人： Harvey I. Cantor , Gary Nabel
IPC分类号： C12N5/0787 , G01N33/554 , G01N33/68
CPC分类号： G01N33/6854 , C12N5/0642 , G01N33/554 , C12N2501/59 , C12N2502/11 , C12N2503/02 , Y10S435/975 , Y10S436/808
摘要： The present invention is directed to an in vitro assay, useful in determining the effectiveness of anti-allergy compounds and/or useful in measuring the degree of sensitivity of a patient to particular allergens.The present invention permits potential anti-allergy agents to be assayed in a number of ways. For example, the binding and dissociation rates of IgE to the mast cells in the presence and the absence of the substance being tested may be measured thereby giving a direct indication of that substance's ability to interfere with the IgE binding reaction. Another measure of a substance's potential as an anti-allergy agent is based upon the release of mediators or other compounds from the mast cells after sensitization by the allergen and exposure of the sensitized cells to the allergen.The present invention generally involves the following steps:(a) sensitizing cloned mast cells to an allergen;(b) exposing sensitized mast cells to the allergen in the presence of a test anti-allergy agent; and(c) measuring the reaction products of step (b) for an indication of test compound effect.
摘要翻译：本发明涉及用于确定抗过敏化合物的有效性和/或可用于测量患者对特定变应原的敏感度的体外测定。本发明允许以多种方式测定潜在的抗过敏剂。例如，可以测量在存在和不存在被测物质时IgE与肥大细胞的结合和解离速率，从而直接指示该物质干扰IgE结合反应的能力。物质作为抗过敏剂的潜力的另一个测量是基于过敏原致敏后暴露于致敏细胞后释放介质或其他化合物从肥大细胞中释放。本发明通常包括以下步骤：（a）使克隆的肥大细胞对过敏原敏感; （b）在测试抗过敏剂的存在下将致敏的肥大细胞暴露于变应原; 和（c）测量步骤（b）的反应产物以表明测试化合物的作用。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式